Xortx Therapeutics Inc (XRTX) Stock Price, Quote & News

Company Profile

XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat gout and progressive kidney disease. Its drug development programs include XRx-026, which is in the third phase for the treatment of gout; XRx-008, which is in the second phase to treat autosomal dominant polycystic kidney disease; XRx-101, which is in the second phase to treat acute kidney injury associated with respiratory virus infection; and XRX-225, w...

Industry: Biotechnology

Sector: Healthcare

Phone: 403-455-7727

Website: www.xortx.com

Address:

3710 – 33rd Street NW, Calgary, Canada

theshortsqueezer2022 Jun. 16 at 4:09 PM

$BCDA and $XRTX are in my top 5 biotech plays

1 · Reply

LookaLike Jun. 15 at 11:30 AM

$XRTX

0 · Reply

BiopharmaWatch_com Jun. 13 at 7:32 PM

🔍 NDA Filings: The Early Signal for Biotech Bulls 🔍 Curious why NDA filings matter? When a biotech files an NDA (New Drug Application), it’s their first shot at FDA approval showing confidence in their clinical data and moving one step closer to a commercial launch. These events often attract smart money early, before PDUFA dates and big headlines. Check out some of the recent NDA catalysts on the radar: $CING (CTx-1301, ADHD) PoA: 85% $NTRB (AVERSA Fentanyl patch) PoA: 60% $AQST (Anaphylm™ for allergic reactions) PoA: 85% $MDAI (DeepView® burn wound system) PoA: 85% $XRTX (XRx-026, gout) PoA: 40% 💡 Investor tip: NDA filing ≠ approval, but high Probability of Approval (PoA) and strong trial data can mean more eyes (and volume) before the FDA’s final say. For more NDA catalysts and PoA breakdowns, check biopharmawatch.com #Biotech #FDA #NDA #Catalysts #Stocks

1 · Reply

avoz Jun. 12 at 5:15 PM

$XRTX Milestones & Comparables IND submission: gout - Q3 2025 PK study results: gout - Q3 2025 Completion of CM&C validation: gout - Q3 2025 Stability studies initiated: gout - Q4 2025 NDA submission: gout - Q1 2026

0 · Reply

LookaLike Jun. 12 at 9:53 AM

$XRTX

0 · Reply

Steelpink Jun. 10 at 7:54 PM

$XRTX $CARM

0 · Reply

Steelpink Jun. 10 at 7:33 PM

$XRTX

0 · Reply

MrMarmalade Jun. 9 at 11:09 PM

$XRTX I’m glad I sold this pos. It’ll probably pop when I least expect it but for now I’m out because their board and ceo seem to give no shits about the investors floating their salaries. Good luck to all of you still in it I’m sure I’ll be eating my words when it pops for you.

0 · Reply

theshortsqueezer2022 Jun. 4 at 11:29 AM

$XRTX only a matter of time…

0 · Reply

MrMarmalade Jun. 3 at 7:21 PM

$XRTX hate being locked in this stock. I know as soon as I sell it something will happen

0 · Reply

XORTX Announces USD $3 Million Offering

Apr 17, 2025, 7:45 PM EDT - 2 months ago

XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

Jan 17, 2025, 5:00 PM EST - 5 months ago

XORTX Announces Change of Auditor

Dec 12, 2024, 9:17 AM EST - 6 months ago

XORTX Announces Presentation at the Rare and Genetic Disease Summit

Oct 18, 2024, 4:00 PM EDT - 8 months ago

XORTX Announces Closing of US$1.5 Million Registered Direct Offering and Concurrent Private Placement

Oct 9, 2024, 5:00 AM EDT - 8 months ago

XORTX Initiates Precision Medicine Program

Sep 13, 2024, 7:00 AM EDT - 9 months ago

XORTX Announces Results of Annual and Special Meeting of Shareholders

Sep 12, 2024, 5:30 PM EDT - 9 months ago

XORTX Announces Re-filing of YE 2023 and Q2 2024 MD&A

Sep 6, 2024, 5:30 PM EDT - 10 months ago

XORTX Reminds Shareholders of Voting Deadline for Upcoming Annual and Special Meeting of Shareholders

Sep 3, 2024, 12:30 PM EDT - 10 months ago

Independent Proxy Advisory Firm ISS Recommends XORTX Shareholders Vote FOR ALL Proposed Items at the Upcoming Annual and Special Meeting of Shareholders

Aug 23, 2024, 7:00 AM EDT - 10 months ago

XORTX Announces Filing and Mailing of the Meeting Documents in Connection with the Annual and Special Meeting of Shareholders

Aug 20, 2024, 7:00 AM EDT - 10 months ago

XORTX Announces Presentation at American Society of Nephrology – Kidney Week 2024

May 17, 2024, 7:00 AM EDT - 1 year ago

XORTX Reprices Balance of Warrants Issued in Connection with October 2021 US IPO

Apr 30, 2024, 1:54 PM EDT - 1 year ago

XORTX Reprices Warrants Issued in Connection with Previous Private Placements

Apr 22, 2024, 7:00 AM EDT - 1 year ago

XORTX Announces Publication of Key Research in ADPKD

Apr 8, 2024, 7:30 AM EDT - 1 year ago

XORTX Welcomes New Member to the Board of Directors

Mar 27, 2024, 5:00 AM EDT - 1 year ago

XORTX Announces New Clinical Advisory Board Member

Mar 19, 2024, 5:00 AM EDT - 1 year ago

XORTX Highlights Achievements of 2023 and Preparation for Registration Clinical Trial

Mar 4, 2024, 7:00 AM EST - 1 year ago

XORTX Finalizes $2.7 Million Prospectus Supplement and Concurrent Private Placement for the Offering of Units

Feb 1, 2024, 8:46 PM EST - 1 year ago

XORTX Files an Amended and Restated Prospectus Supplement for the Offering of Units

Jan 15, 2024, 7:00 AM EST - 1 year ago

XORTX Announces $2 Million Public Offering

Jan 3, 2024, 7:00 AM EST - 1 year ago

XORTX Submits a New Patent for the Treatment of Chronic Kidney Disease

Nov 30, 2023, 7:30 AM EST - 1 year ago

XORTX Announces US ATM Offering

Nov 29, 2023, 7:00 AM EST - 1 year ago

XORTX Meets Nasdaq Continued Listing Requirements

Nov 10, 2023, 7:00 AM EST - 1 year ago

XORTX Clarifies Timing for Share Consolidation

Nov 8, 2023, 5:00 PM EST - 1 year ago

XORTX Announces Share Consolidation

Oct 27, 2023, 5:30 PM EDT - 1 year ago

XORTX Announces Results of Special Meeting of Shareholders

Oct 25, 2023, 5:00 PM EDT - 1 year ago

XORTX Announces Date for Rescheduled Special Meeting of Shareholders

Oct 25, 2023, 7:00 AM EDT - 1 year ago

XORTX Announces Rescheduling of Special Meeting of Shareholders

Oct 12, 2023, 7:00 AM EDT - 1 year ago

XORTX Reports that Independent Proxy Firm, ISS, Recommends Shareholders Vote for the Share Consolidation Resolution

Oct 4, 2023, 7:00 AM EDT - 1 year ago

XORTX Calls Special Meeting of Shareholders

Aug 29, 2023, 7:00 AM EDT - 1 year ago

XORTX Submits Orphan Drug Designation Application to the European Medicines Agency (EMA) to Treat Progressive Kidney Disease

Aug 4, 2023, 5:00 PM EDT - 2 years ago

XORTX Appoints Chief Financial Officer

Jun 23, 2023, 8:51 PM EDT - 2 years ago

XORTX Reminds Shareholders to Vote ahead of the Proxy Voting Deadline for the Company's Upcoming Annual and Special Meeting of Shareholders

May 24, 2023, 7:00 AM EDT - 2 years ago

XORTX Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Deficiency

Apr 21, 2023, 7:00 AM EDT - 2 years ago

XORTX Announces Receipt of FDA Orphan Drug Designation to Treat Autosomal Dominant Kidney Disease

Feb 1, 2023, 7:00 AM EST - 2 years ago

XORTX Announces Submission of Orphan Drug Designation Request for XRx-008 Program to Treat Autosomal Dominant Kidney Disease

Jan 19, 2023, 7:00 AM EST - 2 years ago

XORTX Announces Positive Topline Results from XRX-OXY-101 Clinical Trial

Dec 8, 2022, 7:00 AM EST - 2 years ago

XORTX Announces New Proof of Concept Data in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Nov 28, 2022, 7:00 AM EST - 2 years ago

XORTX Announces Completion of Screening and Enrollment in Bridging Pharmacokinetics Study

Nov 25, 2022, 5:45 PM EST - 2 years ago

XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

Nov 16, 2022, 7:00 AM EST - 2 years ago

XORTX Therapeutics Appoints Stacy Evans, M.D., MBA as Chief Business Officer

Nov 3, 2022, 5:00 PM EDT - 2 years ago

XORTX Presents New Proof of Concept Data at American Society of Nephrology

Nov 3, 2022, 10:15 AM EDT - 2 years ago

XORTX Announces Participation at Upcoming Investor Conferences

Oct 7, 2022, 6:02 PM EDT - 2 years ago

XORTX Announces Closing of US$5 Million Public Offering

Oct 4, 2022, 8:30 AM EDT - 2 years ago

XORTX Announces US$5 Million Public Offering

Sep 19, 2022, 7:00 AM EDT - 2 years ago

XORTX Completes Positive Pre-Phase 3 Meeting with the US Food and Drug Administration

Aug 22, 2022, 7:00 AM EDT - 3 years ago

XORTX Announces Positive Topline Results from Part 2 Pharmacokinetics Bridging Study

Jul 22, 2022, 8:00 AM EDT - 3 years ago

XORTX Reports Annual & Special Meeting Results

Jul 19, 2022, 7:00 AM EDT - 3 years ago

XORTX Announces Submission to European Medicines Agency

theshortsqueezer2022 Jun. 16 at 4:09 PM

$BCDA and $XRTX are in my top 5 biotech plays

1 · Reply

LookaLike Jun. 15 at 11:30 AM

$XRTX

0 · Reply

BiopharmaWatch_com Jun. 13 at 7:32 PM

1 · Reply

avoz Jun. 12 at 5:15 PM

0 · Reply

LookaLike Jun. 12 at 9:53 AM

$XRTX

0 · Reply

Steelpink Jun. 10 at 7:54 PM

$XRTX $CARM

0 · Reply

Steelpink Jun. 10 at 7:33 PM

$XRTX

0 · Reply

MrMarmalade Jun. 9 at 11:09 PM

0 · Reply

theshortsqueezer2022 Jun. 4 at 11:29 AM

$XRTX only a matter of time…

0 · Reply

MrMarmalade Jun. 3 at 7:21 PM

$XRTX hate being locked in this stock. I know as soon as I sell it something will happen

0 · Reply

MrMarmalade Jun. 3 at 6:54 PM

$XRTX this company sucks eggs

0 · Reply

BearTamerTrading May. 30 at 5:45 PM

$XRTX Agreed, this has been a disappointing play so far.

0 · Reply

JL_TradeZ May. 29 at 1:30 PM

$XRTX — eyes on this reversal setup. Private placement priced at $0.88, so that’s the soft floor. If it clears $0.984 with volume, this could squeeze fast. Float is thin, and chart’s tight. Watching for $1.50 → $2.00 upside if it confirms. Still high-risk — offering adds pressure — but setup’s there. Reclaim + momentum = move. Let’s see if it wakes up.

2 · Reply